Thomas R Webb

List of Publications by Year
in descending order

16	1,205	1051969 10	1051228 16
papers	citations	h-index	g-index

17	17	17	2436
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The spliceosome is a therapeutic vulnerability in MYC-driven cancer. Nature, 2015, 525, 384-388.	13.7	392
2	Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Review of Anticancer Therapy, 2009, 9, 331-356.	1.1	206
3	Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing. ACS Chemical Biology, 2011, 6, 582-589.	1.6	155
4	Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome. Nature Communications, 2017, 8, 14060.	5.8	99
5	The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discovery Today, 2013, 18, 43-49.	3.2	89
6	The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget, 2015, 6, 22734-22749.	0.8	60
7	Optimization of Antitumor Modulators of Pre-mRNA Splicing. Journal of Medicinal Chemistry, 2013, 56, 10033-10044.	2.9	57
8	Inhibition of SF3B1 by molecules targeting the spliceosome results in massive aberrant exon skipping. Rna, 2018, 24, 1056-1066.	1.6	42
9	USP39 Deubiquitinase Is Essential for KRAS Oncogene-driven Cancer. Journal of Biological Chemistry, 2017, 292, 4164-4175.	1.6	37
10	A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 406-412.	1.0	16
11	Hereditary retinoblastoma iPSC model reveals aberrant spliceosome function driving bone malignancies. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2117857119.	3.3	13
12	Pharmacodynamic assays to facilitate preclinical and clinical development of preâ€•mRNA splicing modulatory drug candidates. Pharmacology Research and Perspectives, 2015, 3, e00158.	1.1	12
13	An exon skipping screen identifies antitumor drugs that are potent modulators of pre-mRNA splicing, suggesting new therapeutic applications. PLoS ONE, 2020, 15, e0233672.	1.1	11
14	Changes in Alternative Splicing as Pharmacodynamic Markers for Sudemycin D6. Biomarker Insights, 2017, 12, 117727191773055.	1.0	9
15	Improving the Efficiency of the Drug Development by Expanding the Scope of the Role of Medicinal Chemists in Drug Discovery. ACS Medicinal Chemistry Letters, 2018, 9, 1153-1155.	1.3	4
16	Sudemycin Selectively Inhibits Growth of Primary Murine Hematopoietic Cells Expressing Mutant U2AF1. Blood, 2012, 120, 554-554.	0.6	3